Both IL-10 overexpression and treatment with pegylated IL-10 (PEG-IL-10), lead to enhanced expression of IFN-γ and GZMs in tumor-resident CD8+ T cells, thereby promoting their long-lasting cytotoxic ability and favoring tumor rejection in a subset of patients with intermediate to poor risk in renal cell cancer (163). This evidence concerns the gene IL10 and neoplasm.